CEO and President of Penumbra Inc (30-Year Financial, Insider Trades) Adam Elsesser (insider trades) sold 8,000 shares of PEN on 07/13/2020 at an average price of $191.9 a share. The total sale was $1.5 million.
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures. Penumbra Inc has a market cap of $6.93 billion; its shares were traded at around $192.86 with a P/E ratio of 176.94 and P/S ratio of 12.60. Penumbra Inc had annual average EBITDA growth of 56.90% over the past five years. GuruFocus has detected 1 severe warning sign with Penumbra Inc. .
CEO Recent Trades:
- CEO and President Adam Elsesser sold 8,000 shares of PEN stock on 07/13/2020 at the average price of $191.9. The price of the stock has increased by 0.5% since.
Directors and Officers Recent Trades:
- EVP and Chief Business Officer Lynn Rothman sold 200 shares of PEN stock on 07/13/2020 at the average price of $195. The price of the stock has decreased by 1.1% since.
- Director Thomas Wilder sold 230 shares of PEN stock on 07/13/2020 at the average price of $192.47. The price of the stock has increased by 0.2% since.
- Director Bridget O'rourke sold 189 shares of PEN stock on 07/13/2020 at the average price of $192.47. The price of the stock has increased by 0.2% since.
For the complete insider trading history of PEN, click here
.
